Comparative Pharmacology
Head-to-head clinical analysis: GENTACIDIN versus ZINC BACITRACIN NEOMYCIN SULFATE POLYMYXIN B SULFATE HYDROCORTISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTACIDIN versus ZINC BACITRACIN NEOMYCIN SULFATE POLYMYXIN B SULFATE HYDROCORTISONE.
GENTACIDIN vs ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis.
Combination antibiotic and corticosteroid: Neomycin, polymyxin B, and bacitracin are antibiotics that inhibit bacterial protein synthesis, disrupt cell membrane permeability, and inhibit cell wall synthesis, respectively; hydrocortisone is a corticosteroid that suppresses inflammatory responses by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
5-7 mg/kg IV every 24 hours.
Apply 3-4 times daily to affected area as a thin layer. Topical route. Frequency: every 6-12 hours.
None Documented
None Documented
2-3 hours in adults with normal renal function; extended to 24-48 hours in anuria or severe renal impairment, requiring dose adjustment.
Neomycin: 2-3h (systemic, IM); Bacitracin: 1.5h (systemic, IM); Polymyxin B: 6h (systemic, IV); Hydrocortisone: 1.5-2h (systemic). Topical: not applicable due to minimal absorption.
Renal: 95-98% unchanged via glomerular filtration; biliary/fecal: <2%.
Renal: Neomycin (<1% absorbed, remainder fecal), Bacitracin (10-40% renal if absorbed, negligible), Polymyxin B (60% renal over 24h if absorbed), Hydrocortisone (metabolized, <1% unchanged renal; fecal for unabsorbed). Topical: negligible systemic absorption; fecal for unabsorbed.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic